Matthias Preusser
#89,745
Most Influential Person Now
Austrian oncologist
Matthias Preusser's AcademicInfluence.com Rankings
Matthias Preusserphilosophy Degrees
Philosophy
#7391
World Rank
#10599
Historical Rank
Logic
#4445
World Rank
#5738
Historical Rank
Download Badge
Philosophy
Matthias Preusser's Degrees
- Doctorate Medicine Medical University of Vienna
- PhD Internal Medicine Medical University of Vienna
Why Is Matthias Preusser Influential?
(Suggest an Edit or Addition)According to Wikipedia, Matthias Preusser is an Austrian oncologist and Professor of Medical Oncology as well as Head of the Clinical Division of Oncology at the Medical University of Vienna. He is known for his work on neurooncology, Molecular Therapy targets and biomarkers and immunotherapy of cancer.
Matthias Preusser's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- DNA methylation-based classification of central nervous system tumours (2018) (1461)
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
- Brain tumour cells interconnect to a functional and resistant network (2015) (655)
- EANO guidelines for the diagnosis and treatment of meningiomas. (2016) (524)
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody (2011) (456)
- DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. (2017) (447)
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. (2015) (436)
- Current concepts and management of glioblastoma (2011) (429)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
- Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. (2007) (334)
- Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) (2017) (312)
- Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. (2015) (303)
- Prospects of immune checkpoint modulators in the treatment of glioblastoma (2015) (301)
- Molecular targeted therapy of glioblastoma. (2019) (295)
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma (2013) (286)
- Quantitative evidence for early metastatic seeding in colorectal cancer (2019) (267)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (264)
- Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * (2008) (223)
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases (2016) (215)
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases (2012) (213)
- BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. (2012) (203)
- Correlation of immune phenotype with IDH mutation in diffuse glioma (2017) (182)
- Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma (2012) (180)
- Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. (2017) (175)
- The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space (2017) (172)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (171)
- Brain metastases: pathobiology and emerging targeted therapies (2012) (168)
- Invasion patterns in brain metastases of solid cancers. (2013) (168)
- The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry (2009) (165)
- Visualization of Central European tick-borne encephalitis infection in fatal human cases. (2005) (164)
- Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells (2013) (158)
- The Evolving Landscape of Brain Metastasis. (2018) (146)
- Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. (2017) (140)
- PET imaging in patients with meningioma—report of the RANO/PET Group (2017) (135)
- 5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement (2013) (133)
- DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
- Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma (2020) (127)
- Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers (2016) (126)
- Vaccine-based immunotherapeutic approaches to gliomas and beyond (2017) (116)
- Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. (2020) (115)
- Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue (2006) (115)
- Advances in meningioma genetics: novel therapeutic opportunities (2018) (111)
- PET imaging in patients with brain metastasis-report of the RANO/PET group. (2019) (108)
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
- Advances in broad bandwidth light sources for ultrahigh resolution optical coherence tomography. (2004) (105)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. (2021) (104)
- Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis (2013) (103)
- Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium (2006) (102)
- EANO guideline on the diagnosis and management of meningiomas. (2021) (101)
- Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma (2016) (100)
- Angiocentric Glioma: Report of Clinico-Pathologic and Genetic Findings in 8 Cases (2007) (100)
- Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens (2011) (98)
- Activity of T-DM1 in Her2-positive breast cancer brain metastases (2015) (98)
- PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). (2014) (97)
- Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin. (2018) (94)
- Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases (2015) (94)
- Imaging ex vivo healthy and pathological human brain tissue with ultra-high-resolution optical coherence tomography. (2005) (93)
- Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC) (2016) (91)
- Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†. (2020) (91)
- Subcellular localization of disease-associated prion protein in the human brain. (2005) (86)
- Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey (2017) (86)
- Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. (2020) (86)
- Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. (2018) (86)
- Review of cancer treatment with immune checkpoint inhibitors (2017) (85)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (85)
- AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry (2013) (83)
- Dura mater is a potential source of Aβ seeds (2016) (81)
- Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies (2012) (78)
- Brain metastases free survival differs between breast cancer subtypes (2012) (77)
- CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
- Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. (2015) (76)
- Neurocognitive training in patients with high-grade glioma: a pilot study (2010) (76)
- Glioma Survival Prediction with Combined Analysis of In Vivo 11C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning (2017) (75)
- Characterization of the inflammatory response to solid cancer metastases in the human brain (2012) (75)
- Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker (2008) (74)
- PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations (2019) (73)
- FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). (2011) (70)
- NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi (2013) (70)
- The caregivers’ perspective on the end-of-life phase of glioblastoma patients (2013) (69)
- Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo (2008) (68)
- Histopathologic assessment of hot‐spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors (2006) (67)
- Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases (2017) (66)
- Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. (2012) (66)
- Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion (2018) (65)
- Interlaboratory comparison of IDH mutation detection (2013) (63)
- Breast cancer brain metastases responding to primary systemic therapy with T-DM1 (2013) (62)
- BRAF‐Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and CD34 Expression (2014) (62)
- Comparative analysis of NeuN immunoreactivity in primary brain tumours: conclusions for rational use in diagnostic histopathology (2006) (61)
- Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases (2013) (60)
- Malignant glioma: Neuropathology and Neurobiology (2006) (60)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. (2014) (57)
- PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome (2018) (57)
- Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. (2016) (56)
- A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). (2014) (56)
- How we treat glioblastoma (2019) (55)
- Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. (2013) (55)
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. (2013) (55)
- Trabectedin has promising antineoplastic activity in high‐grade meningioma (2012) (55)
- Papillary glioneuronal tumor (2007) (54)
- IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. (2011) (54)
- Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review (2008) (54)
- High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma (2019) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- How we treat patients with leptomeningeal metastases (2019) (53)
- Rosette-forming glioneuronal tumor of the fourth ventricle (2003) (53)
- Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues (2014) (52)
- Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients (2012) (52)
- Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. (2012) (51)
- Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
- Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases (2015) (51)
- Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial (2018) (51)
- Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group (2012) (50)
- The inflammatory microenvironment in brain metastases: potential treatment target? (2015) (50)
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial (2022) (49)
- Nigral burden of α‐synuclein correlates with striatal dopamine deficit (2008) (49)
- O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? (2009) (49)
- Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer (2016) (49)
- Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. (2014) (48)
- Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases (2018) (48)
- Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. (2008) (47)
- Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. (2016) (47)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (46)
- Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting (2005) (45)
- Exploratory investigation of eight circulating plasma markers in brain tumor patients (2012) (45)
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo (2009) (45)
- Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma (2013) (45)
- High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases (2018) (44)
- MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. (2009) (44)
- SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. (2020) (44)
- OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms (2007) (44)
- Primary central nervous system lymphoma: a clinicopathological study of 75 cases (2010) (43)
- Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
- O6‐methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas (2009) (42)
- Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases (2014) (42)
- Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. (2019) (41)
- Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times (2013) (41)
- Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors (2012) (41)
- mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. (2010) (41)
- The landscape of medical oncology in Europe by 2020. (2014) (41)
- Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism (2018) (41)
- SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic (2020) (39)
- Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. (2021) (39)
- Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions (2015) (39)
- Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). (2013) (39)
- EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. (2019) (39)
- A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. (2016) (38)
- microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells (2014) (38)
- Calcium‐binding protein secretagogin‐expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease (2007) (38)
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma (2013) (37)
- Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival (2005) (37)
- Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. (2005) (37)
- Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation (2020) (36)
- Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. (2012) (36)
- Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. (2009) (36)
- 1324PTUMOR-INFILTRATING LYMPHOCYTES (TILS) AND PD-L1 EXPRESSION IN NON- SMALL CELL LUNG CANCER BRAIN METASTASES (BM) AND MATCHED PRIMARY TUMORS (PT). (2014) (35)
- Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. (2020) (35)
- Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas. (2017) (35)
- Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review. (2015) (34)
- BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. (2014) (34)
- 5-ALA-induced fluorescence as a marker for diagnostic tissue in stereotactic biopsies of intracranial lymphomas: experience in 41 patients. (2018) (34)
- PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma (2018) (33)
- Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study (2008) (33)
- Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion (2019) (33)
- Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 (2019) (33)
- Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma (2015) (33)
- Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors (2012) (33)
- NephroCheck data compared to serum creatinine in various clinical settings (2015) (32)
- mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. (2008) (31)
- Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score (2017) (31)
- CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion (2018) (30)
- Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015) (30)
- Biology and clinical management challenges in meningioma. (2015) (30)
- Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. (2016) (29)
- Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. (2017) (29)
- TPPP/p25 in brain tumours: expression in non-neoplastic oligodendrocytes but not in oligodendroglioma cells (2007) (29)
- Non-invasive assessment of intratumoral vascularity using arterial spin labeling: A comparison to susceptibility-weighted imaging for the differentiation of primary cerebral lymphoma and glioblastoma. (2014) (29)
- Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. (2020) (29)
- Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study (2022) (29)
- No prognostic impact of survivin expression in glioblastoma (2005) (28)
- Optimal Management of Brain Metastases from Breast Cancer (2013) (28)
- Assessing MGMT methylation status and its current impact on treatment in glioblastoma. (2015) (28)
- Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases (2019) (28)
- Bilateral striopallidodentate calcification (Fahr's syndrome) and multiple system atrophy in a patient with longstanding hypoparathyroidism (2007) (28)
- Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? (2015) (27)
- Arterial Spin-Labeling Assessment of Normalized Vascular Intratumoral Signal Intensity as a Predictor of Histologic Grade of Astrocytic Neoplasms (2014) (27)
- Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. (2014) (27)
- Targeted Therapies for Melanoma Brain Metastases (2017) (27)
- Diversity of cytogenetic and pathohistologic profiles in glioblastoma. (2006) (26)
- Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers (2013) (26)
- Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer (2014) (26)
- Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis (2012) (26)
- Pleomorphic xanthoastrocytoma with anaplastic features presenting without GFAP immunoreactivity: Implications for differential diagnosis (2005) (26)
- Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report (2014) (25)
- Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma (2017) (25)
- Molecular biology of high-grade gliomas: what should the clinician know? (2014) (25)
- Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients (2017) (25)
- Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate (2010) (25)
- New developments in brain metastases (2018) (25)
- Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry (2013) (25)
- High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T (2019) (25)
- Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations (2017) (24)
- Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors (2012) (24)
- The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction (2018) (23)
- BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy (2014) (23)
- Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. (2016) (23)
- Neurological complications of cancer immunotherapy. (2021) (23)
- Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well‐Preserved Histomorphology, Immunohistochemistry and Nucleic Acids (2010) (23)
- Response to imatinib as a function of target kinase expression in recurrent glioblastoma (2014) (23)
- Anti-angiogenic therapies in brain metastases (2018) (22)
- The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. (2017) (22)
- Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. (2020) (22)
- Elevated blood markers 1 year before manifestation of malignant glioma. (2010) (21)
- High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI (2020) (21)
- Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how? (2012) (21)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna (2016) (21)
- Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status (2016) (21)
- Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases (2020) (21)
- Brain metastasis: opportunity for drug development? (2012) (21)
- Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. (2013) (20)
- Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma (2020) (20)
- Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. (2015) (20)
- Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron (2022) (20)
- Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension (2020) (20)
- ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) (2019) (20)
- Screening for post‐traumatic stress disorders in 1017 cancer patients and correlation with anxiety, depression, and distress (2019) (19)
- Synucleinopathy with features of both multiple system atrophy and dementia with Lewy bodies (2007) (19)
- Blood Alterations Preceding Clinical Manifestation of Glioblastoma (2012) (19)
- Positive troponin T without cardiac involvement in inclusion body myositis. (2005) (18)
- Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases. (2020) (18)
- Prognostic impact of breast cancer subtypes in elderly patients (2016) (18)
- BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors (2016) (18)
- How we treat patients with brain tumour during the COVID-19 pandemic (2019) (18)
- Circulating biomarkers of CNS tumors: an update. (2013) (17)
- Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens (2012) (17)
- Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. (2016) (17)
- Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs (2020) (17)
- Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendroglial Neoplasms and Therapeutic Implications (2004) (17)
- Role of the blood-brain barrier in metastatic disease of the central nervous system. (2018) (17)
- Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2019) (17)
- 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial (2021) (17)
- Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. (2017) (16)
- Frequent overexpression of ErbB – receptor family members in brain metastases of non‐small cell lung cancer patients (2013) (16)
- Neuro-oncology: A step towards clinical blood biomarkers of glioblastoma (2014) (16)
- Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. (2018) (16)
- No Evidence for BRAF-V600E Mutations in Gastroeosophageal Tumors: Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody (2013) (16)
- Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas (2018) (16)
- Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression (2018) (15)
- Prognostic impact of genetic alterations and methylation classes in meningioma (2022) (15)
- Blood BRAFV 600 E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis (2012) (15)
- A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR. (2014) (15)
- High-grade meningiomas: new avenues for drug treatment? (2013) (14)
- Clinical neuropathology practice news 2-2012: BRAF V600E testing (2012) (14)
- Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. (2021) (14)
- Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center (2018) (14)
- In search of a target: PD-1 and PD-L1 profiling across glioma types. (2016) (14)
- A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors (2020) (14)
- Evaluation of Dose-Staged Gamma Knife Radiosurgical Treatment Method for High-Risk Brain Metastases. (2016) (14)
- ROS1 translocations and amplifications in lung cancer brain metastases (2014) (14)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in daily practice: A real-life feasibility analysis at the Medical University Vienna. (2017) (14)
- Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels. (2011) (13)
- Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients (2021) (13)
- Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis (2018) (13)
- DEC1 expression in 1p-aberrant oligodendroglial neoplasms. (2005) (13)
- Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience (2010) (13)
- Milestones of the last 10 years (2017) (13)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? (2018) (12)
- Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo (2016) (12)
- Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases (2020) (12)
- Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours (2020) (12)
- European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL). (2022) (12)
- Immunotherapy of Brain Cancer (2016) (12)
- Immunohistochemical detection of class III β‐tubulin in primary brain tumours: variable expression in most tumour types limits utility as a differential diagnostic marker (2007) (11)
- KINFix – A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens (2015) (11)
- Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study (2014) (11)
- Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials (2021) (11)
- Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort (2019) (11)
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2021) (11)
- Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma (2019) (11)
- Thalidomide as Palliative Treatment in Patients with Advanced Secondary Glioblastoma (2014) (11)
- Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. (2022) (11)
- Cancer immune cycle: a video introduction to the interaction between cancer and the immune system (2016) (11)
- Neuro-oncology in 2016: Advances in brain tumour classification and therapy (2017) (11)
- Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases (2021) (11)
- Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI (2020) (10)
- LAG-3 expression in the inflammatory microenvironment of glioma (2021) (10)
- A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma? (2020) (10)
- Rare Primary Central Nervous System Tumors in Adults: An Overview (2020) (10)
- Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome? (2019) (10)
- Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee (2020) (10)
- Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021? (2021) (10)
- Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens. (2004) (10)
- Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma (2021) (10)
- Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases (2021) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer (2014) (10)
- The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. (2021) (10)
- Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis (2019) (10)
- Applied Precision Cancer Medicine in Neuro-Oncology (2019) (10)
- Biology in prevention and treatment of brain metastases (2013) (10)
- Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. (2019) (10)
- MAP kinase activity supported by BRAFV600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases (2014) (9)
- Prognostic Value of 5-ALA Fluorescence, Tumor Cell Infiltration and Angiogenesis in the Peritumoral Brain Tissue of Brain Metastases (2021) (9)
- New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series (2019) (9)
- microRNA-21 Expression is Elevated in Esophageal Adenocarcinoma After Neoadjuvant Chemotherapy (2015) (9)
- 1081O_PRPROFESSIONAL BURNOUT IN EUROPEAN YOUNG ONCOLOGISTS: A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE (2014) (9)
- Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor (2015) (9)
- EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe (2019) (9)
- Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study (2020) (9)
- PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study (2020) (9)
- Case-Based Review: meningioma. (2016) (9)
- Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma (2020) (9)
- Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single‐centre experience and literature review (2015) (9)
- CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion (2019) (9)
- Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers (2012) (9)
- The PERS(2) ON score for systemic assessment of symptomatology in palliative care: a pilot study. (2016) (8)
- A pilot study of the endomicroscopic assessment of tumor extension in Barrett’s esophagus–associated neoplasia before endoscopic resection (2014) (8)
- MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas (2018) (8)
- Genetic variants associated with colorectal brain metastases susceptibility and survival (2015) (8)
- High plasma-GFAP levels in metastatic myxopapillary ependymoma (2013) (8)
- Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma (2021) (8)
- Autopsy at 2 months after death: brain is satisfactorily preserved for neuropathology. (2007) (8)
- Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. (2020) (8)
- Secretagogin expression in tumours of the human brain and its coverings (2007) (7)
- Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 (2021) (7)
- Analysis of the inflammatory tumor microenvironment in meningeal neoplasms. (2020) (7)
- Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma (2013) (7)
- Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. (2012) (7)
- Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial (2022) (7)
- Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle (2022) (7)
- Outcome evaluation in glioblastoma patients older than 65 years: Importance of individual assessment of treatment tolerance. (2014) (7)
- New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice? (2020) (7)
- Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI (2019) (7)
- Radiomics in neuro-oncological clinical trials. (2022) (6)
- Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study (2019) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors. (2022) (6)
- MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE (2019) (6)
- External validation of the NUn score for predicting anastomotic leakage after oesophageal resection (2017) (6)
- p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction (2020) (6)
- Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo (2010) (6)
- Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab (2021) (6)
- Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. (2015) (6)
- External granular cell layer bobbling: a distinct histomorphological feature of the developing human cerebellum. (2013) (6)
- Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
- CSF and laboratory analysis (tumor markers). (2012) (6)
- The future of targeted therapies for brain metastases. (2015) (6)
- Does the application of diffusion weighted imaging improve the prediction of survival in patients with resected brain metastases? A retrospective multicenter study (2020) (6)
- Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer (2021) (5)
- The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna (2017) (5)
- Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. (2013) (5)
- Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre (2021) (5)
- Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma (2020) (5)
- Lack of P-glycoprotein expression in melanoma brain metastases of different melanoma types. (2016) (5)
- Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature (2021) (5)
- Diagnostic value of 18 F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site (2018) (5)
- Pilot study on sex hormone levels and fertility in women with malignant gliomas (2012) (5)
- ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC (2014) (5)
- Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome (2020) (5)
- PD1 and PD-L1 expression in glioblastoma. (2014) (5)
- Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity (2020) (5)
- Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI (2020) (5)
- IB-02ROLE OF TUMOR INFILTRATING LYMPHOCYTES AND PDL1 EXPRESSION IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM): COMPARATIVE ANALYSIS. (2014) (4)
- Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
- Plasma PD-L1 concentration in patients with brain metastases from solid tumors. (2015) (4)
- MR Fingerprinting—A Radiogenomic Marker for Diffuse Gliomas (2022) (4)
- Postoperative MRI after surgery of brain metastases: Analysis of extent of resection and potential risk factors for incomplete resection. (2020) (4)
- O6.02ANALYSIS OF PD1 AND PD-L1 EXPRESSION IN GLIOBLASTOMA (2014) (4)
- Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. (2017) (4)
- Antiangiogenic Treatment of Meningiomas (2015) (4)
- PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival (2021) (4)
- PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) (2019) (4)
- Brain metastasis research: a late awakening. (2015) (4)
- The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies (2022) (4)
- Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma – molecular testing procedures under scrutiny (2013) (4)
- 363O Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020 (2020) (4)
- Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. (2022) (4)
- Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. (2013) (4)
- Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members (2021) (4)
- Real-life survival in unselected adult glioblastoma patients: A population-based study. (2011) (3)
- Analysis of MGMT promoter methylation status in high grade glioma patients with long term and conventional survival times: A retrospective study (2007) (3)
- Introducing a new ESMO Open article series: how I treat side effects of immunotherapy (2019) (3)
- Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2022) (3)
- Prevalence of pain and its association with symptoms of post‐traumatic stress disorder, depression, anxiety and distress in 846 cancer patients: A cross sectional study (2020) (3)
- A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? (2015) (3)
- Imaging brain morphology with ultrahigh-resolution optical coherence tomography (2003) (3)
- CECOG educational illustrations: the blood–brain barrier and its relevance for targeted cancer therapies and immuno-oncology (2017) (3)
- Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers. (2013) (3)
- Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. (2022) (3)
- Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data (2022) (3)
- Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography (2019) (3)
- Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana? (2022) (3)
- DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma (2022) (3)
- Primary systemic treatment of breast-cancer brain metastases. (2013) (3)
- Presence of D110 antigen expressing immunocompetent cells in glioblastoma associates with prolonged survival (2004) (3)
- Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma (2020) (3)
- Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling (2019) (3)
- Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer. (2022) (2)
- Downregulation of CIC Does Not Associate with Overexpression of ETV1 or MAP Kinase Pathway Activation in Gastrointestinal Stromal Tumors (2014) (2)
- Abstract P6-16-10: Activity of T-DM1 in HER2-positive breast cancer brain metastases (2015) (2)
- DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case–Control Study (2022) (2)
- SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria (2022) (2)
- Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases (2019) (2)
- Development of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings (2022) (2)
- Correlation of plasma PD-L1 detectability with age in glioma patients. (2015) (2)
- Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH? TO THE EDITOR (2018) (2)
- Glioma survival prediction with the combined analysis of in vivo 11C-MET-PET, ex vivo and patient features by supervised machine learning (2017) (2)
- Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma. (2020) (2)
- T-DM1 in HER2-positive breast cancer brain metastases (BM). (2014) (2)
- SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic (2021) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- Immature and absolute platelet count changes and thrombocytopenia in malignant glioma (2011) (2)
- Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy (2022) (2)
- 1OROLE OF PDL1 EXPRESSION AND TUMOR INFILTRATING LYMPHOCYTES (TILS) IN GLIOBLASTOMA (GBM) AND BRAIN METASTASES (BM) (2014) (2)
- A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors (2018) (2)
- Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. (2021) (2)
- Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases (2021) (2)
- Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients. (2013) (2)
- Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer. (2022) (2)
- Bilateral retinal detachment in reactive arthritis: coincidence or association? (2012) (2)
- Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. (2018) (2)
- Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases. (2014) (1)
- Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field (2020) (1)
- Ten years of EC-funded concerted actions on the neuropathology of prion disease: report on the final scientific meeting (31 October-2 November 2003, Baden near Vienna, Austria). (2004) (1)
- DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. (2020) (1)
- Ascending aortic aneurysm causing orthodeoxy-platypnoe syndrome. (2011) (1)
- OS7.4 Outcome of patients presenting with brain metastasis as first manifestation of cancer (2016) (1)
- Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al. (2017) (1)
- Opportunities and challenges for the development of “core outcome sets” in neuro-oncology (2022) (1)
- WHO Guidelines for Diagnosis of Glial Tumours : What Is Old and What Is New ? (2011) (1)
- Neurooncology – ASCO 2010 (2010) (1)
- 53. Genomic characterization of brain metastases identifies drivers of metastatic lung adenocarcinoma (2020) (1)
- Mutational and inflammatory microenvironment characteristics in primary and matched local recurrent non-small cell lung cancer brain metastases. (2018) (1)
- Omics and Prognostic Markers (2010) (1)
- Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group. (2010) (1)
- 2927 Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas (2015) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors (2022) (1)
- Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases. (2018) (1)
- Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. (2013) (1)
- Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer (2023) (1)
- BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy. (2013) (1)
- Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles (2021) (1)
- Emerging systemic treatment options in meningioma (2022) (1)
- Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients. (2014) (1)
- Clinically useful biomarkers in neurooncology (2012) (1)
- Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer. (2017) (1)
- New Approaches with Precision Medicine in Adult Brain Tumors (2022) (1)
- Medical and Neuro-Oncology (2010) (1)
- Treatment with bevazicumab and liposomal doxorubicin for recurrent high-grade gliomas (HGGs). (2010) (1)
- Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort. (2016) (1)
- PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC). (2016) (1)
- 7T HR FID-MRSI Compared to Amino Acid PET: Glutamine and Glycine as Promising Biomarkers in Brain Tumors (2022) (1)
- Association of systemic inflammation with local tumour characteristics and survival in glioma patients (2019) (1)
- NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS (2020) (1)
- Enhanced expression of autophagy‐related p62 without increased deposits of neurodegeneration‐associated proteins in glioblastoma and surrounding tissue – An autopsy‐based study (2022) (1)
- Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patients (2016) (1)
- EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe (2019) (1)
- Brain tumors - other treatment modalities. (2017) (1)
- Management of Brain Metastases: A Case Study (2011) (1)
- 1774P Exploration of torque teno virus (TTV) levels as marker for immune suppression during systemic therapy in advanced solid cancer patients (2021) (1)
- Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors (2020) (1)
- Strong 5-aminolevulinic acid induced flourescence is an intraoperative marker for representative tissue samples in stereotactic tumor biopsies (2011) (1)
- OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients (2019) (1)
- 2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases (2015) (1)
- Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy (2021) (1)
- Feasibility of ultrahigh resolution optical coherence tomography for imaging brain tissue morphology and function (2004) (1)
- Educational video: the role of PD-L1 in the local tumour microenvironment (2016) (1)
- Blood alterations preceding clinical manifestation of glioblastoma. (2012) (0)
- [Therapeutic options for brain metastases]. (2015) (0)
- PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED (2021) (0)
- Faculty Opinions recommendation of Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. (2013) (0)
- P14.14 Adjuvant treatment versus initial observation in newly diagnosed WHO grade II and grade III oligodendroglioma: real-life data from two academic, tertiary care centers in Austria (2021) (0)
- 45P Monocyte subpopulations and myeloid-derived suppressor cells in peripheral blood of cancer patients receiving immune checkpoint inhibition-based treatment (2022) (0)
- Is Brain-Only Metastatic Breast Cancer A Distinct Entity? (2012) (0)
- TMIC-18. ROLE OF MICROGLIA IN THE EARLY STEPS OF THE BRAIN METASTATIC CASCADE (2016) (0)
- The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors (2018) (0)
- Frequent overexpression of HER3 in brain metastases from breast and lung cancer. (2023) (0)
- The Caregivers Perspective On The End-of-Life Phase of Glioblastoma Patients (2012) (0)
- Analysis of 5-ALA induced fluorescence in brain metastases and surrounding brain tissue (2017) (0)
- 1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI (2020) (0)
- Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases. (2015) (0)
- Value of endomicroscopy in the assessment of tumor extension prior to endoscopic resection of Barrett's esophagus-associated neoplasia: A pilot study (2014) (0)
- C.07 Predicting individualized risk of recurrence: development and validation of a DNA-methylation based nomogram in meningioma (2019) (0)
- OS3.6 Development and validation of a DNA methylome-based predictor of meningioma recurrence and meningioma recurrence score (2018) (0)
- Influence of genetic variants of genes potentially associated with colorectal brain metastases on overall survival. (2014) (0)
- Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. (2017) (0)
- Vorspann (1997) (0)
- MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE (2018) (0)
- External validation of the NUn score for predicting anastomotic leakage after oesophageal resection (2017) (0)
- C URRENT OPINION Brain metastasis: opportunity for drug development? (2012) (0)
- Brain metastases of gastro-oesophageal cancer (2013) (0)
- OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials (2021) (0)
- Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis (2021) (0)
- Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. (2023) (0)
- High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients. (2009) (0)
- Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study (2019) (0)
- Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC). (2009) (0)
- Editorial Board / Contents / Guidelines (2014) (0)
- Faculty Opinions recommendation of Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. (2013) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- [Basic principles: signaling pathways and checkpoints]. (2017) (0)
- Abstract LB-046: Evaluation of an assay for on-demand and easy assessment of MGMT gene promoter methylation in glioblastoma patients (2017) (0)
- Molecular analysis of meningioma increases prognostic power: A methylation-based classification and grading system (2018) (0)
- Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC). (2013) (0)
- 69 POSTER Therapeutic effect of everolimus (RAD001) in combination with antiangiongenic chemotherapy for gastric cancer in vivo (2006) (0)
- tumor infiltrating lymphocytes in glioblastoma Running title : PD-L 1 expression in glioblastoma (2017) (0)
- TEMPORARY REMOVAL: PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer. (2022) (0)
- A comparison of 7 Tesla MR spectroscopic imaging and 3 Tesla MR fingerprinting for tumor localization in glioma patients (2023) (0)
- Radiomic Features Define Risk and Are Linked to DNA Methylation Attributes in Primary CNS Lymphoma (2022) (0)
- BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI (2021) (0)
- ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND? (2019) (0)
- Best of ASCO 2020 (2021) (0)
- Outcome and Molecular Characteristics of Young Adult Patients with Newly Diagnosed Primary Glioblastoma: A Study of the Society of Austrian Neurooncology (SANO) (2012) (0)
- Androgen receptor expression in breast cancer brain metastases. (2018) (0)
- Tu1347 Endomicroscopy-Assisted Endoscopic Resection of Barrett's Esophagus-Associated Neoplasia: a Prospective Study Involving 37 Consecutive Patients (2014) (0)
- P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer (2019) (0)
- Development of an updated, standardized, patient-centered outcome set for lung cancer. (2022) (0)
- 1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria (2020) (0)
- NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY (2015) (0)
- P04.09 Tumor infiltrating lymphocytes and programmed death ligand 1 (PD-L1) expression in diffuse and anaplastic gliomas. (2016) (0)
- The value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS). (2017) (0)
- QOL and neurocognitive functions in patients with GBM. (2014) (0)
- Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors (2020) (0)
- CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT (2022) (0)
- New frontiers in neurooncology. (2015) (0)
- Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer (2016) (0)
- NC-04THE COURSE OF QOL AND NEUROCOGNITION IN NEWLY DIAGNOSED PATIENTS WITH GBM (2014) (0)
- Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM). (2014) (0)
- Prognostic role of the EANO ESMO classification of leptomeningeal metastases (2019) (0)
- Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee (2020) (0)
- Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: analysis of 624 patients (2016) (0)
- Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy (2023) (0)
- Pathobiology and Emerging Targeted Therapies in Brain Metastases: Summary of Preusser et al, Acta Neuropathol 2012 (2016) (0)
- 1428P Circulating nutritional biomarkers and their association with survival in patients with metastatic gastroesophageal cancer (2021) (0)
- P18.06 Quality of life and neurocognitive performance of patients with glioma surviving longer than five years after surgery and radiotherapy (2017) (0)
- 1824P Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors (2020) (0)
- P18.13 Cross sectional study of sleeping problems in glioma patients (2017) (0)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (0)
- Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer (2016) (0)
- Meeting report (2004) (0)
- Key Word and Full-Text Search Member of the Pathobiology and Emerging Targeted Therapies in Brain Metastases : Summary of Preusser (2019) (0)
- Prognostic factors in leptomeningeal metastases. (2021) (0)
- 366PACTIVITY OF T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES. (2014) (0)
- CMET-18. EARLY POSTOPERATIVE MRI DETECTS UNEXPECTED RESIDUAL BRAIN METASTASES AFTER RESECTION IN A HIGH FREQUENCY OF CASES: A RETROSPECTIVE ANALYSIS IN THREE SPECIALIZED CENTERS (2017) (0)
- Faculty Opinions recommendation of Anticancer effects of niclosamide in human glioblastoma. (2013) (0)
- Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma (2022) (0)
- LETTERS TO THE EDITOR. Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH? (2018) (0)
- Meningioma research-status quo and quo vadis. (2017) (0)
- The following are summaries of selected presentations from the PCNSM4: Perspectives in Central Ner vous System Malignancies conference held on March 28-29, 2008, in Berlin, Ger many. (2008) (0)
- THROMBOSIS AND HEMOSTASIS Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism (2017) (0)
- 369P Characterization of the inflammatory tumor microenvironment composition in brain metastases after failure of immune checkpoint inhibitor therapy (2021) (0)
- 1400P Initial symptoms and their association with survival in patients with stage II-III gastroesophageal adenocarcinoma (2021) (0)
- No Difference of the Systemic Immune-Inflammation Index as Prognostic Factor for Patients with Adenocarcinoma of the Gastroesophageal Junction With or Without Neoadjuvant Treatment (2018) (0)
- Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer (2022) (0)
- Brain metastases from hepatopancreatobiliary malignancies (2023) (0)
- microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells (2014) (0)
- Neuro-oncology during the COVID-19 pandemic (2021) (0)
- Systemic and local inflammation characteristics in patients with cancer after lung transplantation. (2021) (0)
- Report on a Completed EANO Research Fellowship (2016) (0)
- SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine (2021) (0)
- CTNI-51. NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM (2020) (0)
- Abstract 832: Evaluation of relevance of genes expressed in cancer stem cells and under hypoxia in astrocytic brain tumors (2010) (0)
- Reply to comment on "Analysis of the inflammatory tumor microenvironment in meningeal neoplasms". (2021) (0)
- Bevacizumab apparently shows activity in the management of brain metastases, but currently clinical (2013) (0)
- PP43 RCL2 fixation of neurosurgical specimens: well preserved histomorphology and DNA integrity (2009) (0)
- Editorial Board / Contents / Imprint / Guidelines (2014) (0)
- 1877P Fatigue changes according to systemic therapy type in patients with advanced solid cancer (2020) (0)
- GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION (2019) (0)
- MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA (2018) (0)
- Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC) (2016) (0)
- Prognostic impact of breast cancer (BC) subtype in elderly patients. (2015) (0)
- Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples (2020) (0)
- PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study (2021) (0)
- S1644 ASSOCIATION OF SYSTEMIC CYTOKINE LEVELS WITH RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH GLIOMA (2019) (0)
- Highlights from the literature (2014) (0)
- Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment (2020) (0)
- O1.03DENSITY OF TUMOR INFILTRATING LYMPHOCYTES CORRELATES WITH BRAIN EDEMA AND OVERALL SURVIVAL IN BRAIN METASTASES (2014) (0)
- Correlation of large brain edema with favorable prognosis in patients with single brain metastases. (2012) (0)
- EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection (2023) (0)
- Markers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases (2019) (0)
- Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours. (2023) (0)
- Current Treatment Strategies in Breast Cancer Brain Metastases (2019) (0)
- Tumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases (2019) (0)
- Introducing pro and con discussions in ESMO Open—Cancer Horizons (2022) (0)
- Abstract 4729: Identifying genomic drivers of lung adenocarcinoma brain metastases (2020) (0)
- Activity of T-DM1 in Her2-positive breast cancer brain metastases (2015) (0)
- Cross-sectional survey on thyroideal and gonadal hormones in adult patients with high-grade gliomas. (2010) (0)
- Antiangiogenic treatment approaches in breast cancer (2013) (0)
- Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refrectory to taxane-based neoadjuvant chemotherapy (2013) (0)
- SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES (2019) (0)
- Characterization of candidate tissue and blood biomarkers in a rare cohort of myxopapillary ependymoma patients. (2013) (0)
- die due to Brain Metastases: A Meeting Report from the Annual Meeting of the American Society of (2017) (0)
- P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis (2021) (0)
- NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS (2021) (0)
- Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours (2019) (0)
- Characterization of the inflammatory response to solid cancer metastases in the human brain (2012) (0)
- LS2 METASTATIC BRAIN TUMORS / MENINGIOMAS: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES (2019) (0)
- P08.01RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM) (2014) (0)
- Clinical outcome of GBM long-term survivors. (2011) (0)
- Statistical Indicators for the Analysis of Digitalized Brain Tumor Images (2016) (0)
- Contents of Forthcoming Issues (2008) (0)
- HER3 expression in the primary tumor as marker of metastatic potential in breast cancer patients. (2012) (0)
- Influence of genetic variants of genes potentially associated with brain metastases on overall survival in 70 colorectal cancer patients. (2014) (0)
- Quantitative evidence for early metastatic seeding in colorectal cancer (2019) (0)
- P14.03 Shifting trends and entity-specific aspects in patients with brain metastasis: real-life analysis from 6031 individuals over an observation period of 30 years (2021) (0)
- P12.10 The ROAM / EORTC 1308 trial: Radiation versus observation following surgical resection of atypical meningioma - study update (2017) (0)
- Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses (2021) (0)
- 5-ALA induced fluorescence for intraoperative visualization of specific intratumoral histopathological compartments in newly diagnosed glioblastoma (2017) (0)
- Circulating PD-L1 levels vary across brain tumour entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients (2019) (0)
- P14.25 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) the detection of the primary lesion and staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS) (2016) (0)
- P05.51 Prognostic impact of genetic alterations and methylation class in meningioma (2018) (0)
- Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma (2020) (0)
- 1487P Prognostic impact of thyroid hormone status in resectable gastroesophageal cancer (2020) (0)
- 372MO Melanoma leptomeningeal metastases: A European multicenter cohort (2020) (0)
- Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases (2021) (0)
- A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis. (2019) (0)
- Viewpoint Radiomics in neuro-oncological clinical trials (2022) (0)
- Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial (2023) (0)
- P14.49 Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey (2021) (0)
- Faculty Opinions recommendation of Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. (2015) (0)
- Erratum to: Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. (2021) (0)
- Correction: Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases (2022) (0)
- Dermatitis linearis outbreak associated with Paederus balcanicus in Austria (2022) (0)
- 345MO Treatment associated changes in the inflammatory microenvironment composition of brain metastases (2021) (0)
- Online Database Featuring Author , Key Word and Full-Text Search Management of Brain Metastases : A Case Study (2016) (0)
- 2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases (2015) (0)
- 1462P Prognostic impact of clinical and laboratory nutritional markers in resectable gastroesophageal cancer (2020) (0)
- 2926 Tumor-infiltrating lymphocytes (TILs) and PDL1 expression in lung cancer brain metastases (2015) (0)
- Early postoperative treatment versus initial observation in CNS WHO grade 2 and 3 oligodendroglioma: clinical outcomes and DNA methylation patterns. (2022) (0)
- Androgen Receptor is Expressed in Breast Cancer Brain Metastases. (2021) (0)
- Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study. (2022) (0)
- Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort (2023) (0)
- Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases. (2020) (0)
- Correlation of systemic and local inflammation with survival prognosis in glioma patients. (2019) (0)
- Combined-modality Therapy for Glioblastoma Multiforme at the University of Vienna Austria: Results from 448 Patients (2008) (0)
- CN-06IS HYPOPITUITARISM CLINICALLY RELEVANT IN GLIOMA PATIENTS? - A CROSS-SELECTIONAL TRIAL IN PATIENTS WITH HIGH-GRADE GLIOMAS. (2014) (0)
- 362O Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma (2020) (0)
- P04.03 Analysis of the inflammatory tumor microenvironment in meningeal malignancies. (2016) (0)
- Delta-like ligand 4 (DLL4) of the notch-signaling pathway is expressed in endothelial cells of glioblastoma: Possible target for antiangiogenesis (2006) (0)
- P01.010 Patterns of care in glioma patients surviving beyond ten years (2018) (0)
- Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH? LETTERS TO THE EDITOR (0)
- Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases (2012) (0)
- MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers (2016) (0)
- 1206Endothelial cell-specific deletion of vascular endothelial growth factor receptor 2/kinase insert domain protein receptor and proliferative pulmonary vasculopathy (2018) (0)
- Microvessel density in progressive meningiomas and its influence on time to tumour recurrence. (2004) (0)
- CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY (2018) (0)
- Erratum. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. (2015) (0)
- 343MO Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma (2021) (0)
- The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space (2018) (0)
- Brain metastases: pathobiology and emerging targeted therapies Matthias PreusserDavid CapperAysegul Ilhan-MutluAnna Sophie Berghoff • Peter BirnerRupert BartschChristine MarosiChristoph Zielinski • Minesh P. MehtaFrank WinklerWolfgang WickAndreas von Deimling (2012) (0)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (0)
- Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study. (2012) (0)
- Toxicity management in severe and refractory cases—what we have learned (2022) (0)
This paper list is powered by the following services:
Other Resources About Matthias Preusser
What Schools Are Affiliated With Matthias Preusser?
Matthias Preusser is affiliated with the following schools:
